Select your location

Q3 business highlights at a glance

This podcast summary was generated with the assistance of AI tools based on the Q3/2025 earnings call transcript. While reviewed for accuracy, it may contain errors or interpretations not intended by Teva. For the official record, please refer to the full earnings call transcript.

Share this article:

You might also be interested

3 Trends I’m Watching in Antibody Generation
Research, development, medicine

Shaping the Future of Medicine through Innovation & Collaboration
Chris fox, Eric Hughes

Innovation and Access: How Teva Is Developing the Next Generation of Medicine

3 Trends I’m watching in Pharma Manufacturing Modernization

Q2 business highlights at a glance

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Innovative medicine capsule with human and digital elements merging

The Future of Medicine is Now: 8 Ways Teva is Accelerating Healthcare Innovation Through AI, Advanced Devices, and Global Collaboration

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City